Metastatic pancreatic cancer is one of the most aggressive and highly lethal malignancies,
with an estimated 5-year survival of less than 5%. In 2013, approximately 45,000 new cases …

Pancreatic cancer (PC) incidence rates are rapidly increasing in developed countries, with
half the patients being metastatic at diagnosis. For decades, fluorouracil, then gemcitabine …

Importance Nivolumab and pembrolizumab are approved for treating platinum-refractory
recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Physicians …

Background In a global, phase III, open‐label, noninferiority trial (REFLECT), lenvatinib
demonstrated noninferiority to sorafenib in overall survival and a statistically significant …

Abstract Background CDKN2A‐p16‐Leiden mutation carriers have a high lifetime risk of
developing pancreatic ductal adenocarcinoma (PDAC), with very poor survival. Surveillance …

Background Neoadjuvant therapy is gaining acceptance as a valid treatment option for
borderline resectable pancreatic cancer; however, its value for clearly resectable pancreatic …

Purpose The Avastin in Glioblastoma trial has shown that patients newly diagnosed with
glioblastoma multiforme (GBM) treated with bevacizumab plus radiotherapy and …

Background 5-Fluorouracil (5-FU) is a chemotherapy used in colorectal, head and neck
(H&N) and other cancers. Dose adjustment is based on body surface area (BSA) but wide …

Aim: To assess the cost-effectiveness in Canada of atezolizumab compared with docetaxel
or nivolumab for the treatment of advanced NSCLC after first-line platinum-doublet …

Background: Nab-paclitaxel plus gemcitabine (NAB-P+ GEM) and FOLFIRINOX have shown
superior efficacy over gemcitabine (GEM) in the treatment of metastatic pancreatic ductal …